GFAP and Alzheimer disease: Key strengths of this study include serial measurements of six AD blood biomarkers in a well characterized longitudinal sample of older individuals with up to a 10-year follow up interval, inclusion of a post-mortem cohort with quantification of AD pathology and confirmation of clinical diagnosis, as well as quantification of plasma and brain GFAP levels in a well-characterized transgenic AD mouse model.